Antibodies that specifically bind to a beta oligomers and use thereof

An antibody, tetramer technology, applied in the direction of antibodies, specific peptides, drug combinations, etc., can solve the problems of side effects, difficult to measure Aβ oligomers alone, etc.

Active Publication Date: 2012-05-16
IMMUNAS PHARMA
View PDF6 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, antibody binding to Aβ monomers can cause side effects due to the presence of Aβ monomers in the brain of healthy individuals
[0006] In addition, the amount of Aβ oligomers can be used as an indicator of Alzheimer's disease; however, it is difficult to measure Aβ oligomers alone using conventional anti-Aβ antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies that specifically bind to a beta oligomers and use thereof
  • Antibodies that specifically bind to a beta oligomers and use thereof
  • Antibodies that specifically bind to a beta oligomers and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[1373] Hereinafter, the present invention is specifically described with reference to examples, but should not be construed as being limited thereto.

[1374] method :

[1375] Antigen preparation

[1376] Synthetic Aβ1-42 (Peptide Institute, Inc., Osaka) was dissolved in distilled deionized water or 10 mM phosphate buffer, and incubated at 37°C for 18 hours. Peptides were then resolved using NuPAGE 4-12% Tris-Glycine Gel SDS-PAGE, and after visualization by CBB staining, only Aβ1-42 tetramers not contaminated with Aβ1-42 monomers were excised. Antigens were prepared by finely crushing the tetramer-containing gel or by extracting the tetramer from the gel.

[1377] Preparation of antibody-producing hybridomas

[1378] BALB / c mice were immunized by injecting the antigen prepared by the method described above into their footpads or abdominal cavity. Then, booster immunizations are given six times. Hybridomas were prepared from inguinal lymph node cells or splenocytes ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.

Description

field of invention [0001] This application claims US Provisional Application No. 61 / 212,986, filed April 17, 2009 and US Provisional Application No. , filed February 26, 2010. 61 / 282,549, which is incorporated herein in its entirety by reference. [0002] The present invention relates to antibodies specifically binding to Aβ oligomers and uses thereof. Background of the invention [0003] The number of Alzheimer's disease (AD) patients worldwide exceeded about 26 million in 2006, and it is predicted to continue rising in an aging society (Non-Patent Document 1). However, there are no curative therapeutics that can retard or reverse the progression of Alzheimer's disease, although therapeutics that can retard disease progression are commercially available. [0004] Multiple lines of evidence have shown that memory decline results from synaptic dysfunction triggered by soluble amyloid beta (Aβ) oligomers (see non-patents 2 and 3). Excessive Aβ oligomer accumulation and depo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18A61K39/395A61P25/28C12N15/09G01N33/53
CPCC07K16/18C07K2317/33C07K2317/92G01N2333/4709C07K2317/76G01N2800/2821G01N33/6896A61P25/00A61P25/28A61P43/00
Inventor 横关达己冈本康秀梅田真伊藤俊行今井雪穗藤井忍高松尚文
Owner IMMUNAS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap